Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | KIF11 | P52732 | 4/20 | 0.35 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.35 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TK1 | P04183 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3974948 | 0.90 | LMNA (0.38) | LMNACYP1A2SMN1; SMN2KDM4EKIF11 | |
| SCHEMBL8007614 | 0.82 | SMN1; SMN2 (0.34) | LMNACYP1A2SMN1; SMN2KDM4EAGTR1 | |
| SCHEMBL3974951 | 0.81 | KIF11 (0.50) | KIF11KCNH2 | |
| SCHEMBL28799825 | 0.79 | ALDH1A1 (0.38) | LMNACYP1A2SMN1; SMN2AGTR1MAPT | |
| Lithium SCHEMBL29714938 | 0.78 | ALDH1A1 (0.38) | LMNACYP1A2SMN1; SMN2AGTR1MAPT | |
| SCHEMBL1263157 | 0.76 | KIF11 (0.41) | LMNACYP1A2SMN1; SMN2KIF11AGTR1 | |
| SCHEMBL2491452 | 0.75 | KIF11 (0.51) | KIF11KCNH2ALDH1A1TK1 | |
| Lithium SCHEMBL29904177 | 0.75 | SMN1; SMN2 (0.41) | LMNASMN1; SMN2KDM4EKIF11MAPT | |
| SCHEMBL8843149 | 0.75 | KMT2A (0.40) | LMNASMN1; SMN2KDM4EMAPTALDH1A1 | |
| SCHEMBL29714943 | 0.73 | BCHE (0.35) | LMNAMAPTKCNH2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7504495-B2 | Quencher compositions comprising anthraquinone moieties | EXIQON A/S (DK) | 2009-03-17 | — | — | US | disclosed |
| US-20050227254-A1 | Quencher compositions comprising anthraquinone moieties | QIAGEN GMBH (DE) | 2005-10-13 | — | — | US | disclosed |
| EP-1538154-A1 | Quencher composition comprising anthraquinone moieties | Exiqon A/S (DK) | 2005-06-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050227254-A1 | Quencher compositions comprising anthraquinone moieties | ANXA5, SUN2, ANXA3 | LMNA 522/4885CYP1A2 4571/4885SMN1; SMN2 2628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.